Pacer Advisors, Inc. Krystal Biotech, Inc. Transaction History

Pacer Advisors, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$153.12 - $183.64 $2,143 - $2,570	-14 Reduced 5.56%	238 $43,000
Q1 2024 May 10, 2024	BUY	$108.01 - $179.35 $27,218 - $45,196	252 New	252 $44,000
Q2 2021 Jul 21, 2021	SELL	$62.14 - $81.82 $37,408 - $49,255	-602 Closed	0 $0
Q1 2021 Apr 05, 2021	SELL	$59.42 - $85.46 $356 - $512	-6 Reduced 0.99%	602 $46,000
Q4 2020 Jan 20, 2021	SELL	$40.64 - $61.38 $9,753 - $14,731	-240 Reduced 28.3%	608 $36,000
Q3 2020 Oct 19, 2020	BUY	$37.76 - $48.49 $32,020 - $41,119	848 New	848 $37,000

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.57B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.